Results 71 to 80 of about 27,592 (211)
The role of Coenzyme Q10 in statin-associated myopathy [PDF]
, 2009 Statins, or 3-hydroxyl-3-methylglutaryl coenzyme HMG-CoA reductase inhibitors,\ud are cholesterol-lowering drugs which are frequently used in the primary and secondary\ud prevention of coronary artery disease. Current research and recommendations support\
Kalra, Dr Sanjay
core
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]
, 2017 BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P +5 more
core +2 more sources
Journal of Internal Medicine, EarlyView.Abstract Background Elevated low‐density lipoprotein (LDL) cholesterol causes atherosclerotic cardiovascular diseases. Variables of whole‐body cholesterol metabolism, for example, high cholesterol absorption efficiency, might also be atherogenic, whereas the role of bile acids is controversial.
Piia Simonen +4 more
wiley +1 more source
haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe [PDF]
, 2005 Background NPC1L1 encodes a putative intestinal sterol transporter which is the likely target for ezetimibe, a new type of lipid-lowering medication.
Guy Justin +3 more
core +2 more sources
Journal of Internal Medicine, EarlyView.Abstract Background and Aims High cholesterol absorption efficiency is determined by genetic variation in small intestinal sterol transporters and affects one‐third of individuals. Their risk for atherosclerotic cardiovascular disease (ASCVD) is increased compared with low cholesterol absorbers, despite similar serum lipid concentrations.
Katariina Öörni +7 more
wiley +1 more source
Lipids in Health and Disease, 2018 Background The utility of ezetimibe in preventing cardiovascular outcomes remains controversial. To guide future assessments of the effectiveness of ezetimibe in routine care, we evaluated how this medication has been prescribed to high-risk older adults
Kristin K. Clemens +3 more
doaj +1 more source
Journal of Internal Medicine, EarlyView.Abstract Background Cardiovascular risk factor control reduces the risk of recurrent events after acute coronary syndrome (ACS). Long‐term post‐ACS management is poorly studied. Objectives To assess frequency of low‐density lipoprotein cholesterol (LDL‐C) and systolic blood pressure (SBP) monitoring and target achievement during 3 years post‐ACS ...
Jessica Schubert +8 more
wiley +1 more source
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Lipids in Health and Disease, 2009 Background Ezetimibe (Zetia®) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein ...
Aoyama Naoyoshi +8 more
doaj +1 more source
Using inactivating mutations to provide insight into drug action [PDF]
, 2015 The role of ezetimibe in lowering plasma cholesterol has been established; however, controversy remains about its clinical benefit. A recent study utilizes naturally occurring genetic variation within the NPC1-like 1 gene (NPC1L1) to demonstrate the ...
Corbin, Laura J, Timpson, Nicholas John
core +3 more sources
Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial
Clinical Cardiology, Volume 49, Issue 4, April 2026.The global CLEAR Outcomes Trial was notable for enrolling 48% females. The study data set offers a unique opportunity to identify any differences in demographics, clinical characteristics, and tolerability of treatment with bempedoic acid between females and males with statin intolerance.
Sahar Naderi +9 more
wiley +1 more source